YS HBV 002
Alternative Names: PIKA YS-HBV-002; YS-HBV-002Latest Information Update: 27 May 2024
Price :
$50 *
At a glance
- Originator Yisheng Biopharma
- Developer LakeShore Biopharma
- Class Hepatitis B vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Hepatitis B
Most Recent Events
- 24 May 2024 YS Biopharma is now called LakeShore Biopharma
- 18 Apr 2024 Yisheng Biopharma plans to initiate phase I trial in Hepatitis B in Philippines in June 2024 (IM) (NCT06162299)
- 18 Apr 2024 Philippine Food and Drug Administration approves clinical trial (CTA) application for YS HBV 002 in Hepatitis B